Skip to main content

Research Repository

Advanced Search

Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol‐related cirrhosis patients

Liu, Ken; Yip, Terry C. F.; Masson, Steven; Fateen, Waleed; Schwantes‐An, Tae‐Hwi; McCaughan, Geoffrey W.; Morgan, Timothy R.; Aithal, Guruprasad P.; Seth, Devanshi

Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol‐related cirrhosis patients Thumbnail


Authors

Ken Liu

Terry C. F. Yip

Steven Masson

Waleed Fateen

Tae‐Hwi Schwantes‐An

Geoffrey W. McCaughan

Timothy R. Morgan

Devanshi Seth



Abstract

Background and Aims
The aMAP score was recently devised to predict hepatocellular carcinoma (HCC) development. However, its performance was not tested in alcohol-related cirrhosis (ALC). We aimed to validate the aMAP score in a cohort of ALC patients.

Method
Study participants with ALC from a prior genome-wide association study were included. All participants had a history of high alcohol consumption. Cirrhosis was defined clinically, using fibroscan and/or histology. Patients were followed until the last liver imaging, HCC, liver transplantation (LT) or death with the latter two adjusted as competing risks.

Results
A total of 269 ALC patients were included: male (72.5%), Caucasian (98.9%), median age 56 years, and median Child-Pugh score 7. The median aMAP score was 60: 12.3% low-risk, 35.3% medium-risk and 52.4% high-risk. After a median follow-up of 41 months, 14 patients developed HCC, 27 received LT and 104 died. The aMAP score predicted HCC development (hazard ratio 1.12 per point increase, P < .001) with good separation of cumulative incidence function between risk groups. The area under the time-dependent receiver operating characteristics curve for predicting HCC development was 0.83 at 1 year and 0.82 at 5 years which was similar to ADRESS-HCC and Veterans Affairs Healthcare System scores respectively.

Conclusions
We validated the excellent performance of the aMAP score in ALC and affirm its applicability across wider aetiologies.

Citation

Liu, K., Yip, T. C. F., Masson, S., Fateen, W., Schwantes‐An, T., McCaughan, G. W., Morgan, T. R., Aithal, G. P., & Seth, D. (2022). Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol‐related cirrhosis patients. Liver Cancer International, 3(2), 99-104. https://doi.org/10.1002/lci2.47

Journal Article Type Article
Acceptance Date Feb 26, 2022
Online Publication Date Mar 12, 2022
Publication Date 2022-06
Deposit Date Mar 16, 2022
Publicly Available Date Mar 16, 2022
Journal Liver Cancer International
Print ISSN 2642-3561
Electronic ISSN 2642-3561
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 3
Issue 2
Pages 99-104
DOI https://doi.org/10.1002/lci2.47
Keywords General Medicine
Public URL https://nottingham-repository.worktribe.com/output/7606709
Publisher URL https://onlinelibrary.wiley.com/doi/10.1002/lci2.47

Files





You might also like



Downloadable Citations